TH104 for the Treatment of Pruritus in Primary Biliary Cholangitis

Phase 2 Not yet recruiting 40 enrolled Tharimmune Inc

RandomizedParallel-groupTriple-blindTreatment

Summary

A phase 2a, multicenter, randomized, double-blind, placebo-controlled study of TH104 in primary biliary cholangitis (PBC) participants with moderate to severe pruritus.

Timeline

Start: 2026-06-01
Primary completion: 2027-03-01
Completion: 2027-06-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Nalmefene	Small molecule	16 mg	Other

TH104 for the Treatment of Pruritus in Primary Biliary Cholangitis

Summary

Timeline

Drugs

Indications